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Introduction: With the anticipation of improved outcomes, espe-
cially for patients with early-stage non-small cell lung cancer,
stereotactic body radiation therapy (SBRT) has been rapidly intro-
duced into the thoracic radiation oncology community. Although at
first glance lung SBRT might seem methodologically similar to
conventional radiotherapy, there are important differences in its
execution that require particular consideration. The objective of this
paper is to highlight these and other issues to contribute to the safe
and effective diffusion of lung SBRT. We discuss practical chal-
lenges that have been encountered in the implementation of lung
SBRT at a single, large institution and emphasize the importance of
a systematic approach to the design of lung SBRT services.
Methods: Specific technical and clinical components that were
identified as being important during the development of lung SBRT
at Princess Margaret Hospital are described. The clinical system that
evolved from these is outlined.
Results: Using this clinical framework the practical topics ad-
dressed include: patient assessment, simulation and treatment plan-
ning, tumor and organ at risk delineation, trial set up before treat-
ment, on-line image-guidance, and patient follow-up.
Conclusions: The potential gain in therapeutic ratio that is theoret-
ically possible with lung SBRT can only be realized if the tumor is
adequately irradiated and normal tissue spared. A discussion of the
component parts of lung SBRT is presented. It is a complex process
and specific challenges need to be overcome to effect the satisfac-
tory transition of lung SBRT into routine practice.
Key Words: Stereotactic body radiation therapy, Lung cancer,
Clinical process, Quality assurance.
(J Thorac Oncol. 2008;3: 1332–1341)
There is increasing interest among the oncology commu-nity in the potential advantages of hypo-fractionated,
high-precision radiation therapy, which are embodied by
‘Stereotactic Body Radiation Therapy’ (SBRT). Lung SBRT
has been introduced for patients with early-stage non-small
cell lung cancer (NSCLC) and more recently, pulmonary
metastases from other primary tumors. It represents an evo-
lution of rigid frame intracranial radio-surgery techniques
that were initially developed at the Karolinska Institute in
Sweden in the 1950s.1 From the mid 1990s onwards, reports
of extracranial SBRT appeared from groups in Europe, Japan,
and North America.2–4 Most of the data to support lung SBRT
has been accumulated for patients with medically inoperable
NSCLC and in contrast to what has been achieved with conven-
tionally fractionated radiotherapy (RT),5 initial local control and
survival results have been very encouraging.6,7 Indeed lung
SBRT is already being discussed as a potential option for
patients with medically operable NSCLC.6 Many dose-frac-
tionation regimens for NSCLC SBRT are in use, some of the
most common are 48 Gy in 4 fractions (Japan), 54 or 60 Gy
in 3 fractions (North America), and 60 Gy in 5 or 8 fractions
(Europe).4,8,9 Biologically, these represent very high, ablative
doses of radiation that exceed the conventional tolerance of
certain normal tissues. By way of comparison (and acknowl-
edging the uncertainty in applying such formulae to ex-
tremely hypo-fractionated RT), 70 Gy fractionated in 35
fractions, represents an estimated biologically effective dose
to the tumor of 84 Gy (/  10), compared with 105 to 132
Gy for 48 Gy in 4 fractions or 60 Gy in 5 or 8 fractions and
180 Gy for 60 Gy in 3 fractions.
The acute toxicity associated with lung SBRT is typi-
cally mild and short-lived. Our own experience at Princess
Margaret Hospital (PMH) is that grade 1–2 fatigue, cough,
chest wall pain, and skin erythema are the most common side
effects in the first 3 months after treatment. Although the
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radiobiology of SBRT is incompletely understood,10 there are
now several reports containing somewhat longer follow-up
data for lung SBRT6,11,12 that permit some general observa-
tions about late toxicity. For very peripheral tumors, incor-
porating chest wall structures in the high-dose volume can
lead to side effects that include rib fracture and chest wall
pain.12 Serious toxicity has been attributed to radiation doses
of the order of 60 Gy in 3 fractions to the central airways,11
and there are individual reports of other toxicities including
fatal esophageal ulceration13 and pneumonitis.14 Sometimes it
can be difficult to ascertain the relative contributions of total
dose, fractionation, and treatment technique (including treat-
ment planning margins and image-guidance) to toxicity.
Many treatment centers now possess the technical ca-
pability to deliver lung SBRT. Nevertheless variation in its
delivery15 argues for initiatives that aim to promote effective
learning and dialogue between institutions and enhance the
clinical diffusion of lung SBRT. The aim of this report is to
describe the experience in one institution that has imple-
mented lung SBRT, and in so doing, try to aid in a practical
way, the fast-occurring transition of lung SBRT from clinical
trials to routine clinical treatment. Specific aspects of design-
ing a clinical system to support the safe and effective delivery
of lung SBRT are discussed. Historical aspects, detailed
technical issues, dose selection, or outcomes relating to
SBRT are not comprehensively reviewed. For such topics, the
reader is referred to several other publications e.g.,6,12,16–19 or
to individual SBRT protocols. This manuscript does not
constitute a ‘recipe’ for thoracic SBRT and technical details
are presented to illustrate specific scenarios encountered in
the implementation of SBRT.
PATIENTS AND METHODS
The lung SBRT program at our institution, a large
academic comprehensive cancer center in Canada, com-
menced in fall 2004, and has evolved over the last 3 years.
Important technical and clinical issues that had to be ad-
dressed were identified early on and the treatment process
developed around them. Many of the issues are generic and
can be grouped under the following headings:
Technical Requirements
For SBRT to be successful, it requires accuracy and
precision to consistently irradiate the tumor while simulta-
neously sparing organs at risk (OAR). In recognition of this,
treatment planning and delivery needs to incorporate the
following features: (i) reliable and consistent patient immo-
bilization, for example with a rigid stereotactic body frame or
‘frameless’ semi-rigid evacuated bag, that is comfortable
enough to accommodate extended treatment sessions, (ii)
high-precision imaging for radiation treatment planning that
facilitates tumor delineation and allows assessment of tumor
motion to inform margin selection,20 (iii) the potential to
manage tumor motion in a reproducible fashion, e.g., using
abdominal compression,2 (iv) precise beam shaping and the
use of multiple nonopposing, coplanar and noncoplanar
treatment beams to deliver a highly conformal, robust dose
distribution with rapid high-dose fall-off, (v) accurate and
precise dose-calculation algorithms, and (vi) on-line image-
guidance to accurately verify tumor and OAR location prior
to and during treatment.21
Clinical Requirements
We considered that an SBRT program required (i) a
clinical forum for patient evaluation and discussion, (ii) a
robust quality assurance program, (iii) protocols for treatment
planning and delivery, (iv) an integrated clinical team with
designated roles, and (v) consideration of whether to develop
the SBRT program within the context of a research ethics
board-approved multicenter, or institutional protocol, and if
not, to then put in place adequate independent mechanisms
for patient follow up that is required to ascertain tumor
control and toxicity and validate specific techniques.22
To meet these requirements there are several key steps
in the lung SBRT process. These include patient selection/
assessment, treatment simulation, tumor and OAR delinea-
tion, treatment planning, quality assurance, treatment deliv-
ery, and assessment of outcomes. Figure 1 presents an
overview of the clinical system that was implemented at
PMH to support the delivery of lung SBRT. Each of the
component parts is considered in more detail in the Results
FIGURE 1. An overview of the Lung Stereotactic Body
Radiation Therapy (SBRT) process at Princess Margaret
Hospital (PMH).
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section, with specific examples of issues that we have en-
countered.
RESULTS
Patient Assessment for Lung SBRT
Patients’ individual circumstances will vary and multi-
disciplinary discussion is suggested, with the aim of ensuring
that patients receive the treatment with the best risk/benefit
ratio. There is some retrospective data from Japan reporting that
medically operable patients with stage I NSCLC who received
lung SBRT to a biologically effective dose of100 Gy had an
impressive 5-year overall survival rate of 71%.6 But at
present, most patients with early-stage NSCLC are treated
with surgical resection and SBRT is typically reserved for
patients who are medically inoperable. It is worth noting that
although there is general agreement on what factors contrib-
ute to medical inoperability, the criteria are neither absolute
nor firmly established and their application is a matter of
clinical judgment that may well differ between individuals
and centers. If SBRT is being considered for medically
operable patients then it needs to be discussed in the context
of other treatments that include “standard procedure” surgery
(e.g., lobectomy), lung-sparing surgery (e.g., segmentectomy,
the role of which is being examined by randomized trials) and
conventional RT. In common with many surgical series, we do
not require histologic confirmation in all cases before SBRT. In
some patients the appearance of a new or growing lesion with
increased uptake on positron emission tomography (PET) im-
aging will be deemed sufficient for decision-making. We recog-
nize that individual centers will vary in this regard.
The critical appraisal of a tumor for possible SBRT is
more stringent than for conventional RT and we have found
it useful to consider several specific issues when assessing
treatment options, including (i) tumor location: for SBRT,
ideal lesions are away from central thoracic structures, in-
cluding proximal bronchial tree, esophagus and spinal cord
and other radio-sensitive structures such as stomach, bowel,
heart, brachial plexus, liver, and spleen, (ii) tumor size:
although SBRT protocols have generally allowed for tumors
up to 5 cm maximum dimension, most results are based on
smaller lesions. The median size of the tumors that we have
treated is 2 to 3 cm, (iii) ease of tumor identification on
imaging: ideally the tumor edges should be well visualized on
computed tomography (CT) and not obscured by atelectasis,
although if this is the case, fusion of PET images for treat-
ment planning may be useful, (iv) histology: there is some
concern that bronchoalveolar cancers have a pattern of in-
traalveolar microscopic spread that may not be ideally suited
to the tight treatment planning margins used in lung SBRT,
and (v) number of lesions: we do consider treating multiple
lesions, either in patients who have more than one primary
lung cancer, or oligometastatic disease (see below).
Important patient factors to assess include the ability to
lie in the treatment position for an appropriate length of time.
Patients need sufficient flexibility to maintain the arms in an
elevated position, but where this is not possible, it may be
feasible to treat in an alternative position, such as one arm up
and one arm down. Depending on its location, prior radiation
treatment need not preclude SBRT. Assessing cumulative
dosing does, however, pose a challenge and each case must
be carefully considered by the clinical team-there are no hard
and fast rules.
Distant failure remains a significant problem in medi-
cally inoperable patients treated with SBRT. In terms of
staging patients our present practice is therefore to use mag-
netic resonance imaging (or where contraindicated, CT) of
the brain, CT of the thorax and abdomen, and Fluorodeoxy-
glucose (FDG) PET/CT scan; an isotope bone scan is ob-
tained if PET/CT is not performed. Every patient has pulmo-
nary function testing, although we do not specify lower limits
that would preclude SBRT. In practice, treatment fields are
often small, minimizing the amount of lung damage from RT
and so even patients with extremely limited lung function,
including those on home oxygen, may be candidates for
SBRT, particularly if they have a peripheral lung lesion.
Treatment Simulation
Two issues of critical importance at the time of simu-
lation for lung SBRT are patient immobilization, and assess-
ment of tumor motion.
Patient Immobilization
Reproducible and stable patient positioning is essential
to facilitate accurate treatment and to permit the small mar-
gins typical of SBRT treatment planning. Many different
immobilization devices exist: most common among these are
those incorporating a stereotactic frame23 and those that rely
on evacuated bags. We use the latter (Vac-Lok MEDTEC,
Orange City, IA).
Cranial, as well as extracranial SBRT was initially
developed using a stereotactic frame to localize the target and
guide the beams in three dimensions. This rigid device
surrounds the patient and is often combined with an evacu-
ated bag to immobilize the patient and abdominal compres-
sion to reduce tumor motion. An important function is to
enable the spatial location of the patient and tumor to be
described by an external coordinate system to improve the
accuracy and precision of patient positioning and contribute
to reducing planning margins. Nevertheless by themselves
such frames have been shown to be insufficient for extracra-
nial tumor localization, which still requires the use of some
form of image-guidance. With the frameless image-guided
system that we use, the tumor itself becomes the fiducial.
Initial setup is achieved by the use of traditional external skin
marks and cone-beam CT is then used to correctly reposition
the tumor to the planning location. All three cardinal planes are
assessed and on-line image registration is carried out before and
during treatment. Even though a frame is not used the paradigm
of accuracy, precision and three-dimensional tumor localiza-
tion, hallmarks of stereotactic treatment, prevails.
It is apparent that the ability of simulator units to
accommodate immobilization devices and specific patient
positions will be influenced by the dimensions of the machine
bore and patient factors such as size, anatomy (e.g., kyphosis)
and upper limb flexibility. Compared with conventional RT,
each SBRT treatment can take a long time (e.g., 30–60
minutes) and more effort is needed to ensure that the patient
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is as comfortable as possible to maximize their stability.
Careful positioning in the immobilization device, supporting
the hands and shoulders, and in some patients, premedication
with analgesia (e.g., to prevent shoulder pain) or an anxiolytic
may need to be considered.
Target Motion
Maximizing the therapeutic ratio of SBRT is in part
predicated on maintaining small treatment volumes. This
makes limiting breathing-induced tumor motion important.24
There are several approaches to accounting for motion when
planning lung SBRT. These range from using fixed cranio-
caudal and lateral margins, to characterizing individual tumor
motion and incorporating this into the definition of volumes.
This can be achieved with methods such as fluoroscopy,
‘slow-CT’ or respiratory-sorted (‘4D’) CT. With the latter
technique the combination of maximum-exhale and inhale
free-breathing images (as at PMH), or a maximum intensity
projection can be used to denote the extent of tumor motion.
Assessing tumor motion in real-time, means that mo-
tion management can be instituted at the simulator if it is
excessive (our action level is typically 1 cm in any direc-
tion). Again, there is a choice when it comes to reducing
motion. Our preference is abdominal compression, a simple
and relatively well-tolerated dampening technique that is also
used with frame-based SBRT. Motion is reassessed at the
same simulator session (aiming for 0.5–1 cm). Other op-
tions include the Active Breathing Coordinator that effec-
tively suspends motion and respiratory gating which limits
the ‘beam-on’ time to certain phases of the breathing cycle.
Although mobile, there are data to suggest that tumor move-
ment is often fairly limited and relatively stable. For example,
Franks et al. from PMH evaluated tumor motion using 4DCT
and respiratory-sorted (4D) cone beam computed tomography
(CBCT) and found that in 18 patients 87% of the motion in any
direction on 4D CBCT was 4.5 mm. Eighty-nine percent of
the differences between the 4D treatment planning CT and
CBCT motion were within 2 mm.25 Fewer than 25% of the
patients treated at PMH with lung SBRT have required abdom-
inal compression.
Tumor and OAR Delineation
SBRT is a high-precision technique requiring precise
delineation of both tumor(s) and normal structures. One
approach is described below.
Gross Tumor Volume (GTV)
Using 4DCT imaging, the GTV is delineated on the
exhale 4DCT dataset using lung windows and then again on
the inhale dataset. Any solid portion of the tumor is included
in the GTV contour and surrounding areas of opacification or
haziness are assessed individually. In selected patients intra-
venous CT contrast may help to identify the GTV. Small
volumes and tight margins are desirable in SBRT to reduce
the amount of normal tissue that is irradiated. When PET
imaging is available (either in the diagnostic or preferably,
the treatment position) it is fused to the exhale CT and may
be used to inform the contouring process, especially in
instances where there is a neighboring region of atelectasis.
Potential inaccuracy in the fusion process needs to be recog-
nized and at this point in time the optimal integration of FDG
PET into NSCLC delineation remains unresolved. The ex-
hale-inhale GTV contours are fused in preparation for delin-
eating the clinical target volume.
If respiratory-sorted CT images are unavailable, or if
they are not usable, for example, if there is excessive artifact
(e.g., ‘stepping’ in the images, particularly in the region of the
tumor), or if the patient’s breathing pattern is unstable, then
free-breathing helical images can be used for treatment plan-
ning. If helical images are used, then additional information
about tumor motion (e.g., from fluoroscopy) can still be used
to generate individualized planning margins, or alternatively
a standard margin recipe (e.g., GTV- planning target volume
[PTV] expansion of 10 mm cranio-caudal and 5 mm else-
where) may be used. Although we typically obtain FDG PET
images at treatment planning and fuse these with the planning
CT, the PET is not respiratory-correlated or ‘deblurred’ and it
is at present unclear how to view or segment free-breathing
PET images to best reflect true motion.
Clinical Target Volume
Having characterized the GTV contours a decision
needs to be made as to how much of a margin to add for
suspected microscopic disease.26 In a departure from conven-
tional treatment planning, and in common with others, we do
not at present add a margin for this (and so the clinical target
volume  internal target volume, [ITV]). This is predicated
on the assumption that the margin added to generate the PTV,
the very high doses being used in SBRT and the relatively
isotropic dose fall-off, in combination with image-guidance
should result in any microscopic disease being adequately
irradiated. Early data from our own and other centers that use
this approach show very high local control rates and support
this practice, however, longer-term data are awaited.
Planning Target Volume (PTV)
For the remaining uncertainty a setup margin is re-
quired. A uniform expansion of 5 mm is typically applied to
the 4DCT-based ITV to generate the PTV. In certain circum-
stances, for example OAR proximity, this may be individu-
alized. The margin takes into account such factors as the
tolerance in the image-guidance process and the stability of
patient setup, which should be verified by individual institutions.
OAR Delineation
With the availability of 4DCT imaging we delineate the
normal structures on the exhale dataset for two reasons.
Firstly, the tumor tends to spend proportionately more time
located near this phase of breathing and secondly, using the
dose-volume histogram for lung at full-exhale is generally
more conservative in terms of estimating normal lung spar-
ing. By more accurately identifying actual tumor motion and
improving the conformity of treatment, 4DCT may reduce the
amount of normal tissue that is irradiated.27
The identification of critical structures is another area
where there are important differences with conventional RT,
both in the structures delineated and the accuracy required.
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There is the potential for greater risks to normal tissues with
SBRT. This requires the delineation of central structures
(trachea, proximal bronchial tree, esophagus, heart, and spi-
nal canal), the brachial plexus and other OAR (such as
stomach, bowel, liver, and spleen). This means that a greater
appreciation of imaging anatomy is required. At PMH, this
entailed a learning curve and prompted peer-review of con-
tours. A second Radiation Oncologist from the lung SBRT
team looks at them before treatment planning commences,
and if necessary, they are revised or discussed further within
the SBRT team. They are subsequently reviewed in multidis-
ciplinary SBRT rounds and where necessary we will also
consult with radiologists. Structures far away from the pri-
mary tumor that would not usually be considered an OAR in
conventional treatment may be identified as important, espe-
cially when noncoplanar beams are used. Hypo-fractionation
may also render tissues such as great vessels, trachea, prox-
imal airways, and skin, important dose-limiting structures.
Radiation Treatment Planning
Dose Prescription
Dose is prescribed to the prescription isodose which is
chosen to ensure adequate PTV coverage (typically 95% of
the PTV should receive at least the prescription dose and
99% of the PTV should be covered by at least 90% of the
prescribed dose). The prescription isodose should be between
60 and 90%, where the center of mass of the PTV is
normalized to 100%. Doses greater than 105% of the pre-
scribed dose should be located inside the PTV where sub-
stantial heterogeneity is allowed (for example doses up to 100
Gy would be permitted if 60 Gy was prescribed to the 60%
isodose). In some situations, such as when the tumor is near
the chest wall, it is desirable to try and avoid ‘hot spots’ over
certain normal tissues, in this case the rib and intercostal
tissues, which may be located inside the PTV. In terms of
dose prescriptions, we have two main schedules, each with
their own normal tissue constraints:
a. Fifty-four or 60 Gy in 3 fractions for peripheral tumors
away from critical central structures (outside the ‘zone
of the proximal bronchial tree’ as defined by the Radi-
ation Therapy Oncology Group, [RTOG]11). For these
prescriptions our normal tissue constraints and indices
of plan quality are based on those used in prospective
RTOG studies.19 These criteria represent ‘expert opin-
ion’ that takes into account international experience
with SBRT and are the best we have for such potent
regimens. One area where a practice adjustment has
been made, however, concerns tumors against the chest
wall. In this location rib fracture and chest wall pain are
potential side-effects of SBRT. At PMH T1 tumors in
this location are treated with 48 Gy in 4 fractions.
Prospective evaluation will provide data on tumor con-
trol and the relative incidence of toxicity with this
approach as compared with historical experience.
b. Forty-eight Gy in four fractions for T1 tumors (3 cm)
close to OAR (e.g., against the chest wall). This regi-
men, and the normal tissue tolerances are taken from the
Japanese Clinical Oncology Group 0403 study.15 Once
again these constraints represent ‘expert opinion’ and
they are also being tested prospectively.
Such normal tissue criteria as referred to above repre-
sent present day knowledge and by adopting these constraints
it will be possible to benchmark the outcome data from our
institution against prospective studies.
While selected tumors located within the zone of the
proximal bronchial tree may be considered for treatment, this
is an evolving area and as noted, caution is required. At
present, at PMH for lesions within 2 cm of the proximal
airways, consideration is given to treating selected patients
with extended fractionation  reduced total dose (e.g., 60 Gy
in 8 fractions28 or 50 Gy in 10 fractions). Not all manuscripts
provide details of, or define tumor location and normal tissue
constraints may not be provided. As so often, the ‘devil is in
the detail’ and even among central tumors, some will be more
intimately in contact with critical structures than others.
Sometimes by attending meetings and engaging with expert
practitioners additional practical information can be gleaned.
There are, however, some data on the treatment of central
tumors and the reader is directed to the following references
for example (although many of these describe small or
uncertain numbers of patients and a wide range of dose
schedules).6,9,11,28–32 The largest reported experience may be
from Lagerwaard et al.28 who used a regimen of 60 Gy in 8
fractions for tumors ‘adjacent to the heart, hilus or mediasti-
num.’ In their series of 206 patients, they report using this
schedule in 12%, apparently without significant toxicity (but
follow-up is currently short at a median of 12 months for the
whole group).
Location of Tumor and OAR
Because SBRT plans typically use coplanar and non-
coplanar beams to permit conformal dose distributions and
rapid dose fall-off, organs such as the stomach, bowel, liver
or brachial plexus may be in the irradiated volume, even if
they are far away from the primary tumor (Figure 2) and their
dose-volume histogram must be assessed. There is some
guidance on the tolerance of these organs in the body SBRT
literature.33,34 The composite dose to the skin requires con-
sideration and in situations such as a peripheral tumor, where
beams are close together, or where there is a skin fold, the
dose may be higher than expected, necessitating changes to
the beam angle or energy and tighter constraints.
Treatment Beams
In designing an SBRT treatment the plan should have
high conformity, rapid isotropic dose fall-off and a compact
intermediate to low dose volume. A high degree of confor-
mity serves to reduce high-dose spillage beyond the PTV and
can be described by the ratio of the volume of the prescription
isodose to the PTV. The compactness and shape of the dose
fall off beyond this can be described by the ratio of the
volume of the isodose representing 50% of the prescribed
dose (R50%) to the PTV and the maximum dose at a distance
of 2 cm from the PTV (D2cm). Published tables provide
desirable objectives for these criteria.19 To achieve these, a
total of nine nonopposing treatment beams (e.g., seven co-
Dahele et al. Journal of Thoracic Oncology • Volume 3, Number 11, November 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1336
planar and two noncoplanar) are commonly used at PMH.
Initial beam parameters have been scripted into the planning
system but they can be modified. If the tumor is close to the
spinal canal for example, an OAR expansion, representing the
planning OAR volume is used to account for variation in
patient positioning and motion, and anisotropic fall off can be
engineered to reduce dose to the OAR. Where additional
treatments may be considered in the future (e.g., for coexis-
tent or future lesions) the potential for cumulative dosing to
an OAR needs to be considered and beam arrangements
chosen to minimize this (e.g., to keep the total spinal cord
dose as low as possible).
At our institution, open conformal beams are standard
and intensity modulated radiation therapy (IMRT) is only
used in individual cases (e.g., where OAR structures are very
close to, or within the PTV). In general we feel that the use
of open conformal fields to treat a mobile tumor in only a few
fractions provides a more robust treatment than one that is
delivered using IMRT. Therefore, we only use IMRT when
clinically mandated (e.g., to create subvolumes with different
dose levels inside the PTV). And then only a small number of
segments are usually permitted to reduce the potential influ-
ence of motion on delivered dose.
When evaluating the treatment plan, unexpectedly high
individual beam weightings should prompt further assess-
ment of the. If a minimum field size is used to permit reliable
dosimetry (we use 3  3 cm in conjunction with multileaf
collimator leaves 5 mm) then when tumors are small, the
effective treatment aperture may be larger than the PTV. As
a result conformity/dose spillage constraints may not be met.
Multiple Targets
Multiple tumors may be treated concurrently or sequen-
tially. So far we have treated two lesions in six patients, three
concurrently and three sequentially (the lesions having gen-
erally been considered synchronous or metachronous primary
tumors). Where a decision is taken to treat more than one
lesion simultaneously and they are close together, we have
typically used a single isocenter. In this situation, consider-
ations include whether or not more forgiving ITV-PTVmargins
(i.e., 5 mm) will be required, because it may be difficult to
match two lesions simultaneously to their respective locations
at the time of simulation. Although a single isocenter may
sometimes be associated with reduced conformity and in-
creased dose spillage, it does serve to limit time on the
treatment couch, which should improve patient stability.
Heterogenity Correction (HC)
Although the density along a path through the chest
wall and into the lung to reach the tumor may vary apprecia-
bly, for a tumor in the lung parenchyma, it might be supposed
that the loss of electronic equilibrium may be compensated
for by the greater energy retained by photons passing through
lung tissue. Nevertheless as demonstrated by differences
between plans corrected, or not, for heterogeneity, this is not
always be the case. Nonetheless, the decision to use hetero-
genity correction (HC) in SBRT plans may vary between
centers. Although it is inherently attractive to account for
differences in tissue density along the beam path and better
appreciate the delivered dose, users should be aware that
different planning systems may handle heterogeneity differ-
ently15 and at present there are no clinical data to suggest that
using HC improves outcomes (indeed recent studies, includ-
ing the RTOG 0236 were performed without HC). If HC is
used, then it may affect the total (corrected) dose that is
deliverable and the utility of non-HC corrected, SBRT quality
metrics, especially those relating to intermediate dose volume
and dose fall-off.35 Individual institutions may need to con-
sider modifications to existing quality metrics. Our standard
practice at this point in time is to use HC and this is
performed with the Collapsed Cone Convolution Superposi-
tion algorithm.
With HC, our experience has been that particularly for
small, mobile tumors surrounded by lung parenchyma (such
that the volume of the PTV is considerably greater than that
of the GTV, and the overall PTV density is low), it has often
not been possible to deliver 60 Gy in 3 fractions and simul-
FIGURE 2. Multiple coplanar and noncoplanar treatment beams (A) are typically used in thoracic stereotactic body radiation ther-
apy (SBRT) to achieve dose conformity and rapid high-dose fall-off (B, Green isodose  60 Gy, Light Blue  30 Gy, Orange  18
Gy). The use of noncoplanar beams means that additional organs at risk (OAR) structures such as brachial plexus, proximal airways,
and liver must be contoured so that the radiation dose they will receive can be assessed (C).
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taneously maintain acceptable dose conformity and spillage.
In such cases though, 54 Gy in 3 fractions is often achievable.
Quality Assurance (QA) Including SBRT Rounds
Regular SBRT rounds are a focal point for the multi-
professional, multidisciplinary team that delivers lung SBRT
(e.g., radiation oncologists, physicists, planners, clinical re-
search associates, and treatment therapists). They are seen as
particularly important given the evolving nature of lung
SBRT and the relative immaturity of this technique. They
provide an opportunity to discuss patients, to review treat-
ment plans, serve as a forum for wider technical consider-
ations, education and research, to highlight specific clinical
scenarios and to improve clinical processes. It is useful to
have facilities available for the projection of treatment plans,
patient records, diagnostic images, radiation treatment
records, and verification images from the treatment unit.
Because of its increased requirement for accuracy and
precision, and the lack of an opportunity to make up for
inadequacies in the delivery of any given fraction, robust
quality assurance (QA) is very important in SBRT.20,36 This
includes independent QA of patient immobilization, the
4DCT simulator, linear accelerators, and image-guidance
systems,37,38 as well as tumor/OAR contour and treatment
plan review. If intensity modulated radiotherapy (IMRT) is
being used then additional QA is required on the treatment
unit. A mini multileaf collimator improves treatment confor-
mity, and a linear accelerator with high output will contribute
to reducing overall treatment time. Although larger centers
may have several linear accelerators that are SBRT capable,
machine down time may still pose challenges. We do not
deliver SBRT on units without volumetric cone-beam imag-
ing, nor do we substitute alternative fractionations. On occa-
sion we have had to modify the overall treatment time or
scheduling because of machine maintenance. On this note, it
is worth highlighting that there are weekly SBRT schedules.39
If a machine is down, most problems will be fixed rapidly, but
if not, then adaptation of the treatment schedule should be
feasible. Characterizing the stability of patient immobiliza-
tion systems during SBRT treatment can assist in determining
the adequacy of institutional planning margins.40 We have
demonstrated that tumor drift from its initial location in-
creases after about half an hour from initial localization21 and
therefore use intrafraction CBCT to verify patient stability.
Treatment Delivery
Trial Set Up
A trial setup session at which no treatment is delivered
has been introduced for all patients to provide reliable feed-
back on patient immobilization, positioning and comfort,
stability of the lesion (e.g., same size, no interval develop-
ment of atelectasis or effusion, reproducible motion), con-
touring and margin selection, and to ensure that the treatment
is deliverable as planned (e.g., no treatment unit and patient
or equipment collisions). CBCT imaging allows the match
between CBCT and simulation CT to be verified and tumor
motion reevaluated (see below). It is also a further opportu-
nity to review the treatment plan and potential OARs and a
chance to discuss patient setup and image matching with the
treating therapists. The ability to review these aspects of
treatment off-line is useful as there is less pressure on the
team to make immediate decisions.
This dry run typically takes place 48 to 72 hours before
the scheduled start of treatment to allow enough time for recon-
touring and replanning in the event that problems are identified.
In recognition of the variability in breathing motion, respiratory-
sorted (4D) CBCT images are also reconstructed using in-house
software to further confirm the adequacy of the ITV and PTV,
and the stability of tumor motion.41 Other techniques can also be
used to reevaluate motion. In a review of the outcome of trial
setup for lung SBRT at our institution, we observed a require-
ment for treatment adjustments in 20%, ITV/PTV adjustment in
11% and in 4% of cases, not all of the gantry angles were
achievable, confirming the usefulness of this procedure.
Image-Guidance
CBCT image-guidance to the tumor is a more accurate
means of localization than using bony landmarks.21 Purdie et
al. demonstrated that the mean difference between lesion
localization derived from soft-tissue (tumor) and bony match-
ing was 6.8 mm, and exceeded 13.9 mm 10% of the time.
Therefore, relying on bony anatomy as a surrogate for the
tumor can result in suboptimal localization and verification.
In response to data like these, our present practice is to
localize the tumor using a two-step on-line matching process:
firstly, automatic registration to bony anatomy (spine) which
permits an assessment of rotation and identifies major inac-
curacies in patient setup. Because we cannot at present
correct for rotation (some couch-systems will correct for
this), it is ‘zeroed-out’ prior to step 2: a soft-tissue match in
which the average tumor image on CBCT is colocalized with
the ITV/PTV treatment planning contours. Adequate OAR
sparing also needs to be verified at this point. If rotation is3
to 5 degrees (or less if there is perceived to be too great an
impact on tumor or OAR location) then the patient is re-
moved from the treatment couch and setup again. Patient
position and tumor stability is verified during treatment (typ-
ically before the couch-kick to deliver the final two, nonco-
planar beams) to minimize intrafraction drift in PTV cover-
age or OAR avoidance. Repeat CBCT imaging at the end of
treatment can provide further information on patient stability
and margin adequacy.
When using volumetric image-guidance, the original le-
sion and normal tissue contours, as well as contours derived
from specific isodoses, especially those representing the pre-
scription dose and critical structure constraints, are exported to
the treatment unit so that they can be used during on-line image
matching to verify both tumor and OAR location (Figure 3).
Such frequent use of on-line CBCT during treatment
has facilitated role extension in the SBRT team and radiation
therapists’ autonomously perform image-guidance at PMH.
Deviation beyond specific thresholds leads to a radiation
oncologist being contacted. In certain situations, for example
when the tumor is less visible on CBCT or close to critical
structures, the radiation oncologist may be present for some
or all of the treatment matching, although we recognize that
in some jurisdictions their presence may be mandatory at all
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fractions. All couch shifts made during treatment are re-
corded prospectively for future analysis and all projections
and reconstructed CBCT images are stored. The standard
process that we have instituted for on-line image-guidance
promotes uniformity in practice and improves workflow on
the treatment unit.
On-Treatment Patient Review
Unexpected toxicity needs to be identified to avoid
compromising treatment in which up to one third of the total
dose may be delivered in a single fraction. In most available
series’ low-level acute morbidity predominates and this also
reflects our experience to date.6,42,43
Follow-Up and Outcomes Assessment
Follow-up is essential to fully characterize toxicity and
efficacy. While opportunities for biologic and anatomic im-
aging are now available in many centers, the optimal imaging
paradigm for post-SBRT response assessment has not been
defined. At present our protocol mandates FDG PET/CT
before and 3 months after completing treatment. This helps
staging prior to SBRT and allows early assessment of tumor
and normal tissue metabolism in response to SBRT. Because
imaging appearances post-SBRT may vary from conventional
RT, dialogue between radiologists and oncologists may be
required to best characterize posttreatment findings. As an
example, Takeda et al. recently reported the development of
fibrosis near to the primary tumor a year or more post-SBRT
that can be difficult to distinguish from tumor recurrence44
(Figure 4). The interpretation of post-SBRT imaging often
becomes clearer with sequential scans but in selected patients
histologic evaluation may need to be considered.
Potential late toxicities of SBRT that are not typically
seen (or seen less frequently) in conventional RT include: (a)
rib fracture which may be symptomatic or asymptomatic and
only identified on close scrutiny of follow-up imaging, (b)
partial lung collapse due to central bronchial toxicity, which
should generally be further assessed with bronchoscopy, (c)
chronic chest wall pain which may be neuropathic, prompting
consideration of adjuvant analgesics and if necessary, the
involvement of pain specialists, and (d) soft tissue chest wall
masses that on histologic examination are consistent with
post-SBRT fibrosis. Findings like these will depend in large
part where the tumor and PTV are located. Education and
support are important in informing patients and colleagues,
who may be unfamiliar with SBRT, of its potential side
effects, especially since the apparent incidence of these may
evolve over time as experience with the technique increases,
more patients are treated and follow up lengthens. In practice,
we subject all significant treatment toxicity and suspicion of
treatment failure to multidisciplinary and peer review by the
FIGURE 3. Cone beam CT (CBCT) is used to register the
target and organs at risk to the simulation position, aided by
exported planning contours. Respiratory-sorted CBCT with
internal target volume (ITV) (red) and planning target vol-
ume (PTV) (green) is pictured.
FIGURE 4. Normal tissue changes postlung stereotactic
body radiation therapy (SBRT) demonstrating left rib fracture
and chest wall fibrosis-which was confirmed histologically (A)
and parenchymal lung fibrosis (B).
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lung SBRT team in case there is an indication to change some
aspect of the clinical process. We have established a lung
SBRT clinic to facilitate patient assessment and follow-up.
DISCUSSION
Outside of certain institutions, lung SBRT is a rela-
tively recent incarnation. Furthermore, different treatment
schedules, planning systems and delivery techniques exist.
This argues for a coordinated approach to the deployment of
lung SBRT and highlights the importance of gathering long-
term outcome information and imparting the uncertainty in its
therapeutic ratio to potential patients. Although perhaps out-
wardly similar to conventional lung RT, important differ-
ences have been highlighted. Foremost among these is that
SBRT is inherently less forgiving of inaccuracy. Therefore
particular attention must be paid to patient comfort and
stability, tumor motion, tumor/OAR delineation during plan-
ning, and localization during treatment. Additional checks in
the clinical process are also warranted, including peer review
of contours, trial setup before treatment and SBRT rounds.
The tumor and normal tissue response differs between SBRT
and conventional RT. Coupled with the relatively limited
follow-up data and the potential for long-term survival in
early-stage lung cancer, this means that unexpected toxicity is
possible and protracted follow up is advocated.
Based around the component parts of lung SBRT and
illustrated with specific clinical scenarios, this paper has
described certain features of current lung SBRT practice at
our institution. It highlights the multistep nature of this
treatment technique and emphasizes the importance of a
systematic approach to the design of clinical SBRT services.
At PMH, key features of the SBRT process include multidis-
ciplinary patient selection, peer-review of tumor and OAR
contours, a trial set up/dry run before treatment, SBRT
rounds, and a lung SBRT clinic. Each of these individual
measures, as well as the overall clinical system is subject to
continuous improvement. Managing the transition from clin-
ical trials to a routine treatment technique is an important part
of allowing patients to fully benefit from lung SBRT. Tech-
nical evolution by itself is insufficient and robust clinical
systems are essential, especially for complex treatment tech-
niques. These systems are intended to standardize and en-
hance patient care, maximizing therapeutic gains as well as
treatment efficacy, efficiency, and safety. They are being
augmented by informal SBRT networks that are developing
among interested specialists and by collaboration with indus-
try partners. Benchmarking and the reporting and sharing of
practical experiences and solutions are beneficial to success-
fully achieving change and should be encouraged.45
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